ReviewClinical & developmental immunology2010
Regulation of tumor immunity by tumor/dendritic cell fusions.
Review in Clinical & developmental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries.Plastic and reconstructive surgery · 2014Pooled it
- The influence of cell-cell fusion on cancer heterogeneity and its promise for targeted treatments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Oncolytic Virotherapy in Solid Tumors: A Current Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.Current oncology reports · 2021Review
- Development of Donor Recipient Chimeric Cells of bone marrow origin as a novel approach for tolerance induction in transplantation.Stem cell investigation · 2021Article
- Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.Frontiers in immunology · 2021Review
- The Interplay between MicroRNAs and Cellular Components of Tumour Microenvironment (TME) on Non-Small-Cell Lung Cancer (NSCLC) Progression.Journal of immunology research · 2019Review
- Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.International journal of molecular sciences · 2016Review
- Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.World journal of gastroenterology · 2016Review
- Dendritic cell-based cancer immunotherapy for colorectal cancer.World journal of gastroenterology · 2016Review
- Immunotherapy for colorectal cancer.World journal of gastroenterology · 2013Review
- Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer.Molecular biology reports · 2013Article
- Cell electrofusion using nanosecond electric pulses.Scientific reports · 2013Article
- Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.Oncoimmunology · 2013Review
- Fusions between dendritic cells and whole tumor cells as anticancer vaccines.Oncoimmunology · 2013Article
- Exploiting inflammation for therapeutic gain in pancreatic cancer.British journal of cancer · 2013Review
- Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.PloS one · 2013Article
- The systematic study of the electroporation and electrofusion of B16-F1 and CHO cells in isotonic and hypotonic buffer.The Journal of membrane biology · 2012Article
- IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.Cancer cell international · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.